ATMOSPHERE
Aug 24 2021
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Read More
Teaming Up for Gene Therapy
Aug 22 2021
*This article originally appeared in the McPherson Eye Research Institute Summer 2021 InSights Newsletter Millions of Americans currently battle inherited visual disorders, armed with very few therapeutic options. Recent advances in genome editing, which many believe…
Read More2021 Ophthalmology Grand Rounds (Virtual)
Dec 10 2020
EDUCATION FOR CLINICAL PROFESSIONALS Residents and faculty present and discuss various case studies with the goal of improving clinical care practice. Held weekly throughout the year, grand rounds offers continuing medical education credit for ophthalmologists…
Read More
Can precision medicine treat childhood blindness?
Jan 25 2019
Using stem cells, gene therapy to correct errors in retinal cells A research team at the University of Wisconsin School of Medicine and Public Health has shown that two novel approaches to treating an inherited…
Read More
It’s a Go – The Clinical Trials Unit Embarks on the First Human Gene Therapy Trial in DOVS History
Mar 13 2018
The University of Wisconsin-Madison Department of Ophthalmology and Visual Sciences (DOVS) has formally been announced as a partner site for Nightstar Therapeutics’ STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia. This is the first…
Read More